Showing results (121-130 of 201) with videos related to
Sort By:
Pageof 21
Cancers|February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.International Journal of Cancer|March 9, 2022
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trialElodie Maille, Jérôme Levallet, Fatéméh Dubois, et al.Plos One|August 15, 2017
Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance statusElise Kaspi, Diane Frankel, Julien Guinde, et al.Translational Oncology|September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trialGuénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.Analytical Chemistry|March 3, 2018
BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNAComtet-Louis Andriamanampisoa, Aurélien Bancaud, Audrey Boutonnet-Rodat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.Lung Cancer (Amsterdam, Netherlands)|July 2, 2023
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trialGuénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, et al.Chest|March 11, 2026
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study groupGrégoire Justeau, Laurent Greillier, Florent Vinas, et al.Cancer Immunology, Immunotherapy : CII|June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)Renaud Descourt, Laurent Greillier, Maurice Perol, et al.Pageof 21